Irina V. Ledenyova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Irina V. Ledenyova has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Khidmet Safarovich Shikhaliev
Voronezh State University, Voronezh, Russia
12 shared publications - Mikhail Aleksandrovich Panteleev
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow, Russia
4 shared publications - Nadezhda A. Podoplelova
Center for Theoretical Problems of Physicochemical Pharmakology, 119991 Moscow, Russia
4 shared publications - Nadezhda P. Novichikhina
Department of Organic Chemistry, Faculty of Chemistry, Voronezh State University, 1 Universitetskaya sq., 394018 Voronezh, Russia
4 shared publications - Alexander S. Shestakov
Voronezh State University, Voronezh, Russia
3 shared publications - Vladimir Borisovich Sulimov
M.V. Lomonosov Moscow State University
3 shared publications
Latest Publications
- 1 May 2024
- Published by Springer Nature in Russian Chemical Bulletin
- Vol. 73 (5) , 1342-1351
Synthesis of N,N-dimethylaminomethylene derivatives of 3-mesyl(tosyl)pyrazolo[5,1-c][1,2,4]triazines and their nucleophile-induced transformations
- 1 May 2024
- Published by Springer Nature in Russian Chemical Bulletin
- Vol. 73 (5) , 1342-1351
Synthesis of N,N-dimethylaminomethylene derivatives of 3-mesyl(tosyl)pyrazolo[5,1-c][1,2,4]triazines and their nucleophile-induced transformations
- 2 January 2023
- Published by Wiley in ChemistrySelect
- Vol. 8 (1)
Allylic and Retro‐Allylic Rearrangements upon Bromination of 8,9‐Substituted 4,4,6‐Trimethyl‐4 H ‐Pyrrolo[3,2,1‐ ij ]Quinoline‐1,2‐Diones. New Aspects and Synthetic Applications
Bromination of 4,4,6‐trimethyl‐4 H ‐pyrrolo[3,2,1‐ ij ]quinoline‐1,2‐diones containing an allylic moiety with N ‐bromosuccinimide (NBS) in carbon tetrachloride in the presence of benzoyl peroxide (BPO) and in DMF solution were studied. When using an equimolar amount of NBS in the BPO‐CCl 4 system, the reaction proceeds regioselectively and standardly at the methyl group at position 6 with the formation of 6‐bromomethylene derivatives. In the NBS‐DMF system, monobromination proceeds at position 5 with the migration of a multiple bond by the allylic rearrangement. With a twofold excess of NBS, in both cases a ( Z )‐5‐bromo‐6‐bromomethylene derivative is formed. The 5‐monobromine isomers undergo retro‐allylic rearrangement in N ‐ and S ‐alkylation reactions, resulting exclusively in 6‐ N ‐alkyl and 6‐ S ‐alkyl derivatives, respectively. Similar products are formed by the same reactions with the use of 6‐bromomethylene derivatives.
- 2 January 2023
- Published by Wiley in ChemistrySelect
- Vol. 8 (1)
Allylic and Retro‐Allylic Rearrangements upon Bromination of 8,9‐Substituted 4,4,6‐Trimethyl‐4 H ‐Pyrrolo[3,2,1‐ ij ]Quinoline‐1,2‐Diones. New Aspects and Synthetic Applications
Bromination of 4,4,6‐trimethyl‐4 H ‐pyrrolo[3,2,1‐ ij ]quinoline‐1,2‐diones containing an allylic moiety with N ‐bromosuccinimide (NBS) in carbon tetrachloride in the presence of benzoyl peroxide (BPO) and in DMF solution were studied. When using an equimolar amount of NBS in the BPO‐CCl 4 system, the reaction proceeds regioselectively and standardly at the methyl group at position 6 with the formation of 6‐bromomethylene derivatives. In the NBS‐DMF system, monobromination proceeds at position 5 with the migration of a multiple bond by the allylic rearrangement. With a twofold excess of NBS, in both cases a ( Z )‐5‐bromo‐6‐bromomethylene derivative is formed. The 5‐monobromine isomers undergo retro‐allylic rearrangement in N ‐ and S ‐alkylation reactions, resulting exclusively in 6‐ N ‐alkyl and 6‐ S ‐alkyl derivatives, respectively. Similar products are formed by the same reactions with the use of 6‐bromomethylene derivatives.
- 8 December 2022
- Published by Wiley in ChemistrySelect
- Vol. 7 (46)
Reaction of 1‐Phenacylidene pyrrolo[3,2,1‐ ij ]quinolin‐2‐ones with Cyclic/Acyclic Enaminones and the Anticoagulant Activity of Synthesized Pyrrole‐Quinoline Derivatives
A convenient strategy for the synthesis of pyrroles lineary linked to 4 H ‐pyrrolo[3,2,1 ‐ij ]quinolin‐2(1 H )‐ones is presented. The cyclization of ( E )‐1‐(2‐oxo‐2‐phenylethylidene)‐4 H ‐pyrrolo[3,2,1‐ ij ]quinolin‐2‐ones with linear and cyclic enaminones proceeds both in the presence of p ‐toluenesulfonic acid and triethylamine. The obtained compounds are characterised by atropoisomerism and keto‐enol tautomerism. The synthesized 1‐(2‐phenyl‐1 H ‐pyrrol‐3‐yl)‐4 H ‐pyrrolo[3,2,1‐ ij ]quinolin‐2(1 H )‐ones were studied for anticoagulant activity.
- 8 December 2022
- Published by Wiley in ChemistrySelect
- Vol. 7 (46)
Reaction of 1‐Phenacylidene pyrrolo[3,2,1‐ ij ]quinolin‐2‐ones with Cyclic/Acyclic Enaminones and the Anticoagulant Activity of Synthesized Pyrrole‐Quinoline Derivatives
A convenient strategy for the synthesis of pyrroles lineary linked to 4 H ‐pyrrolo[3,2,1 ‐ij ]quinolin‐2(1 H )‐ones is presented. The cyclization of ( E )‐1‐(2‐oxo‐2‐phenylethylidene)‐4 H ‐pyrrolo[3,2,1‐ ij ]quinolin‐2‐ones with linear and cyclic enaminones proceeds both in the presence of p ‐toluenesulfonic acid and triethylamine. The obtained compounds are characterised by atropoisomerism and keto‐enol tautomerism. The synthesized 1‐(2‐phenyl‐1 H ‐pyrrol‐3‐yl)‐4 H ‐pyrrolo[3,2,1‐ ij ]quinolin‐2(1 H )‐ones were studied for anticoagulant activity.
- 1 September 2022
- Published by Pleiades Publishing Ltd in Russian Journal of Organic Chemistry
- Vol. 58 (9) , 1225-1232
Synthesis and Anticoagulant Activity of New Functionalized 4H-Pyrrolo[3,2,1-ij]quinolin-2-ones
The reduction of 4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-diones with aqueous hydrazine hydrate selectively involved the C1=O carbonyl group to give the corresponding 4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-ones within a few hours. The reduction products were condensed with aldehydes and acetone to afford new 1-[(het)arylmethylidene]- and 1-(propan-2-ylidene)-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-ones in 59–78% yield. The reaction of 4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-ones with N,N-dimethylformamide dimethyl acetal, followed by transamination with primary amines led to the formation of 1-{[(het)arylamino]methylidene}-4H-pyrrolo[3,2,1-ij]quinolin-2-ones in 65–83% yield. The synthesized compounds were evaluated for their anticoagulant activity by measuring inhibition of blood coagulation factors Xa and XIa.
- 1 September 2022
- Published by Pleiades Publishing Ltd in Russian Journal of Organic Chemistry
- Vol. 58 (9) , 1225-1232
Synthesis and Anticoagulant Activity of New Functionalized 4H-Pyrrolo[3,2,1-ij]quinolin-2-ones
The reduction of 4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-diones with aqueous hydrazine hydrate selectively involved the C1=O carbonyl group to give the corresponding 4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-ones within a few hours. The reduction products were condensed with aldehydes and acetone to afford new 1-[(het)arylmethylidene]- and 1-(propan-2-ylidene)-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-ones in 59–78% yield. The reaction of 4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-ones with N,N-dimethylformamide dimethyl acetal, followed by transamination with primary amines led to the formation of 1-{[(het)arylamino]methylidene}-4H-pyrrolo[3,2,1-ij]quinolin-2-ones in 65–83% yield. The synthesized compounds were evaluated for their anticoagulant activity by measuring inhibition of blood coagulation factors Xa and XIa.
- 1 October 2021
- Published by Pleiades Publishing Ltd in Russian Journal of Organic Chemistry
- Vol. 57 (10) , 1592-1599
Synthesis of New 1-Hydroxy-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-one Derivatives
Aldol addition of acyclic and cyclic ketones to 4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-diones afforded the corresponding 1-substituted 1-hydroxy-4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-ones. The short-time reduction of 4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-diones with sodium tetrahydridoborate gave 1-hydroxy-4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-ones.
- 1 October 2021
- Published by Pleiades Publishing Ltd in Russian Journal of Organic Chemistry
- Vol. 57 (10) , 1592-1599
Synthesis of New 1-Hydroxy-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-one Derivatives
Aldol addition of acyclic and cyclic ketones to 4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-diones afforded the corresponding 1-substituted 1-hydroxy-4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-ones. The short-time reduction of 4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-diones with sodium tetrahydridoborate gave 1-hydroxy-4,4,6-trimethyl-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-ones.
- Open Access
Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa
Coagulation factor Xa and factor XIa are proven to be convenient and crucial protein targets for treatment for thrombotic disorders and thereby their inhibitors can serve as effective anticoagulant drugs. In the present work, we focused on the structure–activity relationships of derivatives of pyrrolo[3,2,1-ij]quinolin-2(1H)-one and an evaluation of their activity against factor Xa and factor XIa. For this, docking-guided synthesis of nine compounds based on pyrrolo[3,2,1-ij]quinolin-2(1H)-one was carried out. For the synthesis of new hybrid hydropyrrolo[3,2,1-ij]quinolin-2(1H)-one derivatives, we used convenient structural modification of both the tetrahydro- and dihydroquinoline moiety by varying the substituents at the C6,8,9 positions. In vitro testing revealed that four derivatives were able to inhibit both coagulation factors and three compounds were selective factor XIa inhibitors. An IC50 value of 3.68 μM for was found for the best factor Xa inhibitor and 2 μM for the best factor XIa inhibitor.
Open AccessSynthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa
Coagulation factor Xa and factor XIa are proven to be convenient and crucial protein targets for treatment for thrombotic disorders and thereby their inhibitors can serve as effective anticoagulant drugs. In the present work, we focused on the structure–activity relationships of derivatives of pyrrolo[3,2,1-ij]quinolin-2(1H)-one and an evaluation of their activity against factor Xa and factor XIa. For this, docking-guided synthesis of nine compounds based on pyrrolo[3,2,1-ij]quinolin-2(1H)-one was carried out. For the synthesis of new hybrid hydropyrrolo[3,2,1-ij]quinolin-2(1H)-one derivatives, we used convenient structural modification of both the tetrahydro- and dihydroquinoline moiety by varying the substituents at the C6,8,9 positions. In vitro testing revealed that four derivatives were able to inhibit both coagulation factors and three compounds were selective factor XIa inhibitors. An IC50 value of 3.68 μM for was found for the best factor Xa inhibitor and 2 μM for the best factor XIa inhibitor.
- Open Access
- 28 March 2020
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 19 (1) , 139-157-157
Blood coagulation in the 21st century: existing knowledge, current strategies for treatment and perspective
Disorders in the blood coagulation system are the leading cause of death and disability in the modern world. So the search for new drugs that can prevent pathological thrombosis, while not affecting normal hemostasis, becomes more relevant than ever. Recent studies has been a revolution in the understanding of the principles of work and the regulation of blood coagulation. In addition, new, more effective approaches to drug development have now appeared. For example computer simulation methods that can significantly reduce the time and resources spent on the search for new candidate molecules. In the review, the blood clotting system, the molekular mechanisms of thrombosis, the role of blood coagulation factors Xa and XIa, and the urgency of developing new inhibitors of these targets are shown, and the most interesting inhibitors of factors Xa and XIa are presented.
- 28 March 2020
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 19 (1) , 139-157-157
Open AccessBlood coagulation in the 21st century: existing knowledge, current strategies for treatment and perspective
Disorders in the blood coagulation system are the leading cause of death and disability in the modern world. So the search for new drugs that can prevent pathological thrombosis, while not affecting normal hemostasis, becomes more relevant than ever. Recent studies has been a revolution in the understanding of the principles of work and the regulation of blood coagulation. In addition, new, more effective approaches to drug development have now appeared. For example computer simulation methods that can significantly reduce the time and resources spent on the search for new candidate molecules. In the review, the blood clotting system, the molekular mechanisms of thrombosis, the role of blood coagulation factors Xa and XIa, and the urgency of developing new inhibitors of these targets are shown, and the most interesting inhibitors of factors Xa and XIa are presented.
- Open Access
- 31 December 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (4) , 136-152
Modern methods for the development of new drugs that affect the hemostatic system
The blood coagulation system plays an important role in health and disease. It is a complex network of proteolytic reactions that is activated during injuries and controls the formation of a fibrin clot. Although new components and reactions have not been discovered for thirty years, during this time there has been a revolution in understanding of how this system works and what enzymes are the optimal targets for the therapy. At the same time, new methods of drug development, first of all, computer docking, which are ideally suited for the discovery of inhibitors of blood clotting enzymes, have appeared. In this review, an attempt has been made to correlate the lines of development of new ideas about the mechanisms of coagulation, new methods of searching for drugs and their combination, thanks to which now there are more and more potentially interesting molecules that can change the face of the anticoagulant therapy in the near future. In the review, molecular modeling methods, primarily docking, which are increasingly used at the initial stage of developing new drugs, the role of docking at the initial stage of developing new inhibitors are briefly considered and the structure of the active centers of factors Xa and XIa, which determines their interaction with inhibitors, are discussed in detail.
- 31 December 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 18 (4) , 136-152
Open AccessModern methods for the development of new drugs that affect the hemostatic system
The blood coagulation system plays an important role in health and disease. It is a complex network of proteolytic reactions that is activated during injuries and controls the formation of a fibrin clot. Although new components and reactions have not been discovered for thirty years, during this time there has been a revolution in understanding of how this system works and what enzymes are the optimal targets for the therapy. At the same time, new methods of drug development, first of all, computer docking, which are ideally suited for the discovery of inhibitors of blood clotting enzymes, have appeared. In this review, an attempt has been made to correlate the lines of development of new ideas about the mechanisms of coagulation, new methods of searching for drugs and their combination, thanks to which now there are more and more potentially interesting molecules that can change the face of the anticoagulant therapy in the near future. In the review, molecular modeling methods, primarily docking, which are increasingly used at the initial stage of developing new drugs, the role of docking at the initial stage of developing new inhibitors are briefly considered and the structure of the active centers of factors Xa and XIa, which determines their interaction with inhibitors, are discussed in detail.
- 1 January 2018
- Published by Pleiades Publishing Ltd in Russian Journal of General Chemistry
- Vol. 88 (1) , 73-79
Unexpected Reaction of Ethyl 4-(Chloromethyl)pyrazolo- [5,1-c][1,2,4]triazine-3-carboxylates with Thiourea and Its Mechanism
The reaction of ethyl 4-(chloromethyl)pyrazolo[5,1- c][1,2,4]triazine-3-carboxylates with thiourea in dimethylformamide involves ANRORC rearrangement (Addition of the Nucleophile, Ring Opening, and...
- 1 January 2018
- Published by Pleiades Publishing Ltd in Russian Journal of General Chemistry
- Vol. 88 (1) , 73-79
Unexpected Reaction of Ethyl 4-(Chloromethyl)pyrazolo- [5,1-c][1,2,4]triazine-3-carboxylates with Thiourea and Its Mechanism
The reaction of ethyl 4-(chloromethyl)pyrazolo[5,1- c][1,2,4]triazine-3-carboxylates with thiourea in dimethylformamide involves ANRORC rearrangement (Addition of the Nucleophile, Ring Opening, and...
- 1 October 2017
- Published by Springer Nature in Chemistry of Heterocyclic Compounds
- Vol. 53 (10) , 1128-1133
Chemospecific reactions of as-triazine ring reduction in sulfonyl derivatives of pyrazolo[5,1-c][1,2,4]triazines
- 1 October 2017
- Published by Springer Nature in Chemistry of Heterocyclic Compounds
- Vol. 53 (10) , 1128-1133
Chemospecific reactions of as-triazine ring reduction in sulfonyl derivatives of pyrazolo[5,1-c][1,2,4]triazines